Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petrylak DP, de Wit R, Chi KN et al (2020) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 21:105–120. https://doi.org/10.1016/s1470-2045(19)30668-0

Article  CAS  PubMed  Google Scholar 

McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853–1857. https://doi.org/10.1200/jco.1997.15.5.1853

Article  CAS  PubMed  Google Scholar 

Pronzato P, Vigani A, Pensa F et al (1997) Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20:519–521. https://doi.org/10.1097/00000421-199710000-00018

Article  CAS  PubMed  Google Scholar 

Witte RS, Elson P, Bono B et al (1997) Eastern cooperative oncology group Phase II Trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589–593. https://doi.org/10.1200/jco.1997.15.2.589

Article  CAS  PubMed  Google Scholar 

Sonpavde G, Pond GR, Choueiri TK et al (2016) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69:634–641. https://doi.org/10.1016/j.eururo.2015.07.042

Article  CAS  PubMed  Google Scholar 

Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II Trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104:1627–1632. https://doi.org/10.1002/cncr.21370

Article  CAS  PubMed  Google Scholar 

Furubayashi N, Hori Y, Morokuma F et al (2021) Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Mol Clin Oncol 14:91. https://doi.org/10.3892/mco.2021.2253

Article  CAS  PubMed  PubMed Central  Google Scholar 

Challita-Eid PM, Satpayev D, Yang P et al (2016) Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003–3013. https://doi.org/10.1158/0008-5472.Can-15-1313

Article  CAS  PubMed  Google Scholar 

Rosenberg J, Sridhar SS, Zhang J et al (2020) EV-101: A Phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38:1041–1049. https://doi.org/10.1200/jco.19.02044

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsubara N, Yonese J, Kojima T et al (2023) Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med 12:2761–2771. https://doi.org/10.1002/cam4.5165

Article  CAS  PubMed  Google Scholar 

Taguchi S, Kawai T, Ambe Y et al (2023) Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study. Int J Urol 30:1180–1186. https://doi.org/10.1111/iju.15300

Article  CAS  PubMed  Google Scholar 

Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458. https://doi.org/10.1002/1097-0142(19891215)64:12%3c2448::aid-cncr2820641209%3e3.0.co;2-7

Article  CAS  PubMed  Google Scholar 

von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077. https://doi.org/10.1200/jco.2000.18.17.3068

Article  PubMed  Google Scholar 

Bellmunt J, Ribas A, Eres N et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966–1972. https://doi.org/10.1002/(sici)1097-0142(19971115)80:10%3c1966::aid-cncr14%3e3.0.co;2-w

Article  CAS  PubMed  Google Scholar 

Dogliotti L, Cartenì G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 Trial. Eur Urol 52:134–141. https://doi.org/10.1016/j.eururo.2006.12.029

Article  CAS  PubMed  Google Scholar 

Alfred Witjes J, Max Bruins H, Carrión A et al (2024) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85:17–31. https://doi.org/10.1016/j.eururo.2023.08.016

Article  CAS  PubMed  Google Scholar 

Nakagawa R, Izumi K, Toriumi R et al (2024) Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma. Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyae101

Article  PubMed  PubMed Central  Google Scholar 

Rawlings AV (2006) Ethnic skin types: are there differences in skin structure and function? Int J Cosmet Sci 28:79–93. https://doi.org/10.1111/j.1467-2494.2006.00302.x

Article  CAS  PubMed  Google Scholar 

Nguyen MN, Reyes M, Jones SC (2021) Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis. JAMA Dermatol 157:1237–1239. https://doi.org/10.1001/jamadermatol.2021.3450

Article  PubMed  PubMed Central  Google Scholar